S. Wood

Rationale and first results of developing at-risk (prodromal) criteria for bipolar disorder.

M. Berk, J. Klosterkötter, A. Bechdolf, 2012, Current pharmaceutical design.

Can antipsychotic dose reduction lead to better functional recovery in first‐episode psychosis? A randomized controlled‐trial of antipsychotic dose reduction. The reduce trial: Study protocol

C. Pantelis, A. Fornito, S. Wood, 2018, Early intervention in psychiatry.

ENACT: a protocol for a randomised placebo-controlled trial investigating the efficacy and mechanisms of action of adjunctive N-acetylcysteine for first-episode psychosis

M. Berk, P. McGorry, K. Allott, 2019, Trials.

Neuroimaging and emerging psychotic disorders: The Melbourne ultra-high risk studies

M. Yücel, C. Pantelis, D. Velakoulis, 2007, International review of psychiatry.